Halozyme Therapeutics HALO paid Forbes-Tate $70K for lobbying in Q1 2026 · Health Issues, Medicare

Trade details

Type: Lobbying report
Amount: $70,000
Quarter: Q1 2026
Stock: Halozyme Therapeutics HALO
Client: Halozyme Therapeutics
Reported: 26/04/18

Up 16.7% from last quarter

What else happened in Halozyme Therapeutics around then

Filed or reported within 30 days of the trade day · 03/01~04/30

Halozyme Therapeutics's other lobbying reports

Halozyme Therapeutics
LobbyingHalozyme Therapeutics
Lobbying
Halozyme Therapeutics
HALO
$80K
$80K
Reported 07/20
for Q2
Halozyme Therapeutics
LobbyingHalozyme Therapeutics
Lobbying
Halozyme Therapeutics
HALO
$60K
$60K
Reported 01/18
for Q4 2025
Halozyme Therapeutics
LobbyingHalozyme Therapeutics
Lobbying
Halozyme Therapeutics
HALO
$60K
$60K
Reported 25/10/18
for Q3 2025
Halozyme Therapeutics
LobbyingHalozyme Therapeutics
Lobbying
Halozyme Therapeutics
HALO
$60K
$60K
Reported 25/07/18
for Q2 2025
Halozyme Therapeutics
LobbyingHalozyme Therapeutics
Lobbying
Halozyme Therapeutics
HALO
$60K
$60K
Reported 25/04/15
for Q1 2025